Lice Clinics of America introduces pesticide-free take-home solution
SALT LAKE CITY — Lice Clinics of America on Tuesday initiated the nationwide launch of its at-home Lice Remover Kit, which contains a non-toxic liquid gel that kills lice, detangles hair and facilitates the removal of dead lice and eggs.
"Our innovative and science-based solutions now offer consumers the ability to cure lice infestations at one of our urgent care clinics or in the comfort of their own home," stated Claire Roberts, CEO of Lice Clinics of America. "And unlike other over-the-counter products, ours even smells good, which is a testament to our desire to provide a pleasant user experience in an unpleasant situation."
With the emergence of pesticide resistant "super lice," the new Lice Remover Kit is a pesticide-free innovation that is guaranteed to end even super lice infestations, the company claimed.
"The CDC reports that 6 to 12 million new infestations of head lice occur in U.S. families each year. Many of these families struggle to find an effective solution to remove the lice," cmmented Krista Lauer, medical director of Lice Clinics of America. "As a physician, I have seen many families suffer from lice infestations and they simply do not know what to do. The Lice Remover Kit is an extremely cost effective do-it-yourself solution to successfully cure head lice infestations."
The product launch is built around an innovative YouTube and Facebook digital advertising campaign that will run in areas where the product has local retail distribution. The "Lice Apocalypse" campaign video mixes engaging humor with educational content on pesticide-resistant super lice and how families can cure it.
The Lice Remover Kit is available now in select retail locations nationwide, including CVS, Target, Walmart, Giant Eagle, HEB and Safeway. This launch and availability of the Lice Remover Kit furthers Lice Clinics of America's global reach and positioning as experts for curing lice infestations.
Disruptive packaging innovation drives growth of Performix Iridium line
OAK BROOK, Ill. — TricorBraun helped disrupt the sports nutrition category with the launch of a "square" Peformix Iridium line of workout supplements. The line featured a packaging upgrade to what was on the market — a square tub vs. the standard industry round tub.
"The Performix brand is built around disrupting the space and bringing new benefits to sports nutrition and the packaging had to reflect the ground-breaking product within," commented Matt Hesse, CEO Performix. "The key objective was to create aesthetics that fall in line with the formulation with regard to disruption. We chose to work with TricorBraun because they have shown a propensity for being able to visualize and achieve breakthrough packaging to disrupt the sports nutrition category. Plus, they are fantastic innovators."
"The intent of the Performix Iridium product line is to be the premium trade up option for consumers who want to add higher order benefits to their physical well-being such as cognitive priming, perpetual strength and expedited muscle recover," added Brent Moore, VP operations Performix. "TricorBraun has proven to be an excellent partner by helping us develop processes for managing inventory as well as executing rush orders. TricorBraun has also helped us manage cash flow in this period of high growth. The Performix Iridium line, in part due to the packaging, has risen by 27% of brand sales in one year. Together, we've developed an effective system for managing logistics/shipments to co-manufacturers."
There were challenges in bringing the square package to market. "Whenever you move away from traditional packaging and bottle design with established industry specifications, it is critical that you redefine form, fit and function for your custom solution," noted Jon-Paul Genest, VP commercial engineering at TricorBraun. "Our process is such that with proper management and creative engineering we're able to preserve the design intent and the vision of the brand owner."
Consumers will find the products squared off and stacked, front and center, at GNC.
IM HealthScience presents clinical evidence of FDgard efficacy
CHICAGO — IM HealthScience submitted clinical data highlighting an advance in the management of functional dyspepsia with FDgard demonstrated unprecedented symptom reduction and rapid relief of FD symptoms in patients in only 24 hours.
"These study results are uniquely important and represent an advance in the management of functional dyspepsia," stated Michael Epstein, chief medical advisor for IM HealthScience. "We believe that FDgard possesses anti-inflammatory, analgesic and gastro-protective properties, which likely are responsible for the rapid relief and steady improvement of FD symptoms in patients even when used as an add-on therapy to commonly used, off-label medications to treat FD, as demonstrated in the FDREST study," he said. "In particular, many FD symptoms flare within 2 hours after a meal, so the fast action seen in this FDgard study is an important advance."
The data was presented during Digestive Disease Week, a gastroenterology meeting.
FDgard showed effective symptom reduction and rapid relief of FD symptoms in a sub-group of FD patients with epigastric pain syndrome and postprandial distress syndrome. Additionally, the study findings showed that FDgard as an add-on product improved FD symptoms in patients already using commonly used, off-label medications prescribed for FD, such as proton pump inhibitors and histamine receptor 2 antagonists, anticonvulsants, antibiotics, antihistamines, antidepressants and antacids as rescue medications.
FD is often characterized as persistent or recurring indigestion with no known organic cause and is an area of high unmet medical need. Currently, off-label medications are used to treat FD as there is no FDA-approved pharmaceutical product for the condition, IM HealthScience stated.
Data from the landmark, multi-centered, post-marketing, parallel group, U.S-based study, entitled FDREST (Functional Dyspepsia Reduction and Evaluation Safety Trial), showed that patients with FD who received FDgard versus a control arm of placebo plus commonly used, off-label FD medications experienced a statistically significant reduction in PDS symptoms and near statistical significance in EPS symptoms at 24 hours. In spite of the polypharmacy and use of rescue medications after 48 hours of first dose, FDgard helped further improve symptoms at 4 weeks.
At the 24 hour mark, there was a 14% improvement of EPS symptoms from baseline and a 9.9% reduction of PDS symptoms from baseline.
At 4 weeks, approximately 75% of the EPS and PDS patients in the FDgard arm reported substantial symptom improvement vs. approximately half in the control arm.
An estimated 62% of FD patients suffer from EPS, while an estimated 73% of FD patients suffer from PDS. The overlap of EPS and PDS, which are those FD patients who suffer from both syndromes, is estimated to be 35%.